CCM
XBIT icon

CAAS Capital Management’s XBiotech XBIT Stock Holding History

CAAS Capital Management’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-58,047
Closed -$997K – 1317
2021
Q1 		$997K Sell
58,047
-80,269
-58% -$1.5M 0.01% 785
2020
Q4 		$2.17M Buy
+138,316
New +$2.55M 0.02% 479

Other funds holding XBIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return

CAAS Capital Management's XBIT Position: Q2 2021 in Review

CAAS Capital Management sold out of XBiotech (XBIT) in Q2 2021, closing a stake of 58,047 shares — an estimated $997K sold.

CAAS Capital Management first reported a position in XBIT in Q4 2020 and held it in 2 quarters. The position peaked at $2.17M in Q4 2020. 56 funds tracked by Wall St. Rank hold XBIT as of Q2 2021.

  • CAAS Capital Management reported no remaining XBiotech position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 58,047 XBiotech shares in Q2 2021, an estimated $997K.
  • CAAS Capital Management first reported a position in XBiotech in Q4 2020 and held it in 2 quarters.
  • CAAS Capital Management's XBiotech position peaked at $2.17M in Q4 2020.
  • 56 funds tracked by Wall St. Rank held XBiotech as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.